arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

LIGAND PHARMACEUTICALS INC

LGND
$293.13 ▼ -7.75 (-2.58%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Bullish
auto_awesome

Analytical Summary

LIGAND PHARMACEUTICALS INC shows strong fundamentals with top-quartile Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $5.8B
Dividend Yield
Revenue Growth 14.1%
Op. Margin 33.6%
ROIC 1.0%
FCF / Share $2.44
Trailing P/E
Price / Book 5.9x
FCF Yield 0.8%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$51.72M
↑ +14.1%
Net Income Profit after all expenses
$-13.35M
↑ +68.6%
Operating Margin Operating profit as % of sales
33.6%
↑ +44.7% 67th
FCF / Share Free cash flow per share
$2.44
↑ +265.0%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
81
Returns
74
Financial Health
96
Cash Quality
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 67 quarters